Viking Therapeutics' stock recently tanked after reporting clinical trial results for an oral anti-obesity candidate. The ...

European stocks fell Thursday as investors weighed ongoing concerns about the artificial-intelligence boom and data showing gains in business activity. The composite purchasing managers' index for the ...

Demand for Novo Nordisk A/S’s weight-loss blockbuster Wegovy is getting a boost in the UK from an unexpected corner: ...

Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for the long term. In a report released on August 13, Seamus Fernandez from Guggenheim maintained a Buy rating on Eli Lilly and ...

Sure, nobody goes around boasting, "We're Number Two!" But in certain circumstances, coming in second has its advantages.

Hundreds of people may have been exposed to rabies in Wyoming, Eli Lilly has a new GLP-1 pill to help people lose weight and ...

In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing financial toxicity and logistical barriers.

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

Eli Lilly's top neuroscience executive, Anne White, is retiring after three decades with the drugmaker. Eli Lilly on Wednesday said White will remain in her post as executive vice president and ...

Novo Nordisk is a sector leader in the fast-growing GLP-1 market, boasting strong fundamentals. Click here to read why I rate ...

In a study known as CROWNS-2 published in JAMA, the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 ...